Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

August 7, 2026Posted inBiotechnology

Novo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.

Post navigation

Previous Post
tau-protein-linked-to-alzheimer’s-disrupts-nerve-cells’-energy-producing-mitochondria Tau protein linked to Alzheimer’s disrupts nerve cells’ energy-producing mitochondria
Next Post
BioMarin axes $270M rare disease asset after missing phase 3 endpoint

Recent Posts

  • Cigar, Cigarillo, and Pipe Smoking: Lung Cancer Risk and Screening Eligibility
  • How Low Gravity and Pressure Affect Space Manufacturing of Carbon-Fiber Structures
  • Calreticulin-targeted L-asparaginase–flagellin conjugate boosts Salmonella’s antitumor effectiveness
  • Porous Reaction-Bonded Silicon Nitride: Size Effects in Pressureless Nitriding of Binder-Jetted Silicon
  • Short-Term Animal-Product Restriction Rapidly Alters Human Proteogenomic Profiles

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top